Moderate dose steroids
Phase 3Small molecule
Moderate dose steroids is one of 52 small molecule programs targeting Pneumonia. It is currently in Phase 3.
2
Indications
5
Total Trials
5
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Moderate dose steroids
QQingyuan Zhan
Phase 3
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pneumonia3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moderate dose steroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- QQingyuan Zhan